Effect of molsidomine on spontaneous ventricular fibrillation following myocardial ischemia and reperfusion in the dog.
The effect of the novel antianginal agent molsidomine on the incidence of spontaneous ventricular fibrillation during myocardial ischemia and reperfusion was investigated in the anesthetized dog. Molsidomine was administered as an intravenous bolus at the dose of 0.05 mg/kg. Twenty minutes later, the left anterior descending coronary artery was occluded for 90 min. During the occlusion period, molsidomine was given as a continuous intravenous infusion at the dose of 0.5 micrograms/kg per ml per min. After release of the occlusion, the animals that survived were monitored for another 30 min. Control animals received saline. In the control animals, coronary occlusion was accompanied by an increase in heart rate, heart contractility, left ventricular end-diastolic pressure, and blood pressure as well as by ventricular arrhythmias. Molsidomine either abolished or reduced both hemodynamic and electrical changes. During the reperfusion period, 10 out of 12 control animals died, and the deaths were from ventricular fibrillation; one out of eight molsidomine-treated animals also died of ventricular fibrillation. It is postulated that the protective effect of molsidomine rests on its hemodynamic effects resulting in a shift in blood flow toward the ischemic zones and, consequently, in an increase in ventricular electrical stability.
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D005260:Female; D008026:Ligation / Q000009:adverse effects; D008297:Male; D008981:Molsidomine; D010069:Oxadiazoles / Q000494:pharmacology*; D013558:Sydnones / Q000494:pharmacology*; D013610:Tachycardia / Q000209:etiology; D014693:Ventricular Fibrillation / Q000209:etiology / Q000517:prevention & control*
D000959:Antihypertensive Agents; D010069:Oxadiazoles; D013558:Sydnones; D008981:Molsidomine